BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025

BiomX Inc. (NYSE American: PHGE), a clinical-stage biotechnology company specializing in innovative phage therapies aimed at combating pathogenic bacteria, is poised to announce its third quarter 2025 financial results and significant program updates on November 12, 2025, before the U.S. markets open. This event promises to provide shareholders and the public with crucial insights into the company's financial performance and the progress of its pipeline aimed at addressing chronic diseases with unmet clinical needs.

The company is scheduled to host a conference call and a live audio webcast at 8:30 a.m. Eastern Time, where management will delve into the financial results and discuss ongoing and upcoming programs. BiomX encourages participants to register at least five minutes before the start of the call and highlights that those opting not to engage directly with management may find it easier to listen via the webcast option.

BiomX specializes in developing natural and engineered phage cocktails, utilizing its proprietary BOLT (BacteriOphage Lead to Treatment) platform to tailor phage compositions that target specific bacterial strains. This approach positions BiomX at the forefront of addressing the pressing health challenge posed by antibiotic-resistant bacteria, offering a novel treatment solution for chronic conditions.

For those interested in following the event, additional details for accessing the conference call and webcast are available through links provided by the company. Furthermore, the live and archived versions of the webcast can be found in the Investors section of BiomX's website.

Overall, this upcoming financial results announcement is a pivotal moment for BiomX as it continues to advance its mission of providing engineered phage therapies to meet critical health care demands.

BiomX Inc. (NYSE American: PHGE) is set to release its third-quarter 2025 financial results and provide crucial updates on its clinical programs on November 12, 2025. Investors and stakeholders should approach this date with a strategic perspective, given the company’s focus on pioneering phage therapy aimed at tackling antibiotic-resistant bacterial infections and chronic diseases with substantial unmet needs.

As BiomX continues to advance its pipeline of natural and engineered phage therapies, the third-quarter results will likely shed light on the progress of its clinical trials, financial health, and upcoming strategic initiatives. Key indicators to watch include revenue growth, R&D expenses, and any updates on the regulatory pathway for its lead product candidates. Positive data or advancements could enhance investor confidence, while disappointing results might trigger volatility.

The broader landscape for biotechnology, specifically phage therapy, remains promising but fraught with risk, as market acceptance and regulatory hurdles are significant factors. With the recent global push against antibiotic resistance, BiomX's position is strategically advantageous, but the market remains competitive with emerging players and evolving technologies.

Given the upcoming conference call on November 12, investors should stay informed and consider participating in the Q&A session to gain further insights from management. The conference will be streamed live, enabling real-time engagement.

In conclusion, while the immediate focus on the upcoming earnings report is critical, stakeholders should maintain a long-term perspective in assessing BiomX's viability in the biopharmaceutical sector. Monitoring program developments, market conditions, and regulatory changes will be vital for informed investment decisions leading into the event and beyond.